2000
Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
Bensen W, Zhao S, Burke T, Zabinski R, Makuch R, Maurath C, Agrawal N, Geis G. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. The Journal Of Rheumatology 2000, 27: 1876-83. PMID: 10955327.Peer-Reviewed Original ResearchMeSH KeywordsAbdominal PainAnti-Inflammatory Agents, Non-SteroidalArthritis, RheumatoidCelecoxibCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDigestive SystemDouble-Blind MethodDyspepsiaFemaleHumansIsoenzymesMaleMembrane ProteinsMiddle AgedNaproxenNauseaOsteoarthritisProspective StudiesProstaglandin-Endoperoxide SynthasesPyrazolesRisk FactorsSulfonamidesTime FactorsTreatment OutcomeConceptsUpper gastrointestinal tolerabilityUpper GI symptomsSevere abdominal painComposite endpointAbdominal painGastrointestinal tolerabilityGI symptomsIndependent predictorsRheumatoid arthritisRelative riskCOX-2-specific inhibitorsUpper GI tolerabilityTreatment group patientsDose-response relationshipGI tolerabilityPlacebo patientsGroup patientsCumulative incidenceParallel groupClinical trialsPlaceboPatientsCelecoxibTolerabilityEndpoint
1999
The Etiology and Outcome of Cerebral Ventriculomegaly at Term in Very Low Birth Weight Preterm Infants
Ment L, Vohr B, Allan W, Westerveld M, Katz K, Schneider K, Makuch R. The Etiology and Outcome of Cerebral Ventriculomegaly at Term in Very Low Birth Weight Preterm Infants. Pediatrics 1999, 104: 243-248. PMID: 10429002, DOI: 10.1542/peds.104.2.243.Peer-Reviewed Original ResearchConceptsBronchopulmonary dysplasiaPreterm infantsCorrected ageIndependent predictorsCerebral ventriculomegalyBirth weightGrade 3Low birth weight preterm infantsBirth weight preterm infantsMaternal educationLow birth weight survivorsCause of ventriculomegalyDevelopment of ventriculomegalyGrades of IVHIncidence of handicapWeight preterm infantsMonths' corrected ageAdverse neurodevelopmental outcomesLow birth weightYears' corrected ageAdverse cognitive outcomesLogistic regression analysisYears of ageApgar scoreNeurodevelopmental handicap
1997
Antecedents of Cerebral Palsy in a Multicenter Trial of Indomethacin for Intraventricular Hemorrhage
Allan W, Vohr B, Makuch R, Katz K, Ment L. Antecedents of Cerebral Palsy in a Multicenter Trial of Indomethacin for Intraventricular Hemorrhage. JAMA Pediatrics 1997, 151: 580-585. PMID: 9193243, DOI: 10.1001/archpedi.1997.02170430046010.Peer-Reviewed Original ResearchConceptsCranial US findingsIntraventricular hemorrhageUS findingsWeight infantsBronchopulmonary dysplasiaPeriventricular leukomalaciaCerebral palsyNeonatal intensive care unitCerebral palsy ratesActive treatment groupIntensive care unitSurfactant replacement therapyIncidence of CPPalsy rateHospital daysPreterm infantsCohort followIndependent predictorsMulticenter trialNeurologic examinationCare unitReplacement therapyUltrasonographic scansBirth weightCranial US